BRISTOL MYERS SQUIBB CO

NYSE: BMY·Princeton, New Jersey·

Price
$62.93
Base IV
$80.20

Valuation snapshot

Below base case

At $62.93, the price sits between our bear case ($31.13) and base case ($80.20).

Values per share, from an .

No growth
…
Loading earnings power
Base case
$80.20
above today's price · range $31.13–$154.97
Price vs base case
22% below
$62.93 against $80.20
Base casevalued by DCF
Price vs base
Priceclose 11‑16

Whisker on the base case runs bear $31.13 to bull $154.97. Values per share.

Price against each value

Bear case
$31.13
Price 102% above
No growth
…
—
Base case
$80.20
Price 22% below
Researched bygpt-6.1-sol
Valuation Nov 11, 2026 · Price as of Nov 16, 2026How we got here

What does Bristol Myers Squibb do?

Bristol Myers Squibb makes prescription medicines doctors use to treat cancers and blood cancers, prevent strokes and clots, control autoimmune inflammation, and manage heart-muscle disease and schizophrenia.

It brought in $50B of sales in the 12 months to Sep 2026.

Led by Chris Boerner, Chief Executive Officer since 2023. Chris Boerner, Board Chair and Chief Executive Officer

Cobenfy 100 mg/20 mg capsulesImage: U.S. National Library of Medicine
Industry
Healthcare
Based in
Princeton, New Jersey
Trades on
NYSE as BMY

Here is where each dollar a customer pays ends up. Out of every $1 of sales in the 12 months to Sep 2026, about 18¢ was left as profit after every cost, interest and tax. The biggest cost is making what it sells, 31¢ of every dollar.

  • Making what it sells31¢
  • Research and development21¢
  • Sales, marketing and admin15¢
  • Everything else, including interest11¢
  • Tax4¢
  • Left as profit18¢
Totals of the four quarters to Sep 2026, from the company's own filings.

Who pays Bristol Myers Squibb, and for what?

Bristol Myers Squibb invents, makes and sells prescription medicines for serious diseases, mainly cancer, blood disorders, immune diseases, heart disease and brain disorders. It earns money by selling these medicines while patents protect them from cheaper copies. It also earns some licensing and royalty income from partners.

Most of its medicines are sold to drug wholesalers, distributors and specialty pharmacies such as McKesson, Cencora and Cardinal Health, with smaller amounts sold to hospitals, clinics, retailers and government agencies; about 69% of 2025 revenue came from the United States.

  • Growth Portfolio

    Newer medicines the company expects to drive future sales, including Opdivo, Orencia, Yervoy, Reblozyl, Breyanzi, Camzyos, Sotyktu and Cobenfy. Sales rose 17% in 2025 to $26.4 billion.

    Cobenfy 100 mg/20 mg capsulesImage: U.S. National Library of Medicine
  • Legacy Portfolio

    Older medicines that are losing or will soon lose patent protection: Eliquis, Revlimid, Pomalyst, Sprycel and Abraxane. Sales fell 15% in 2025 to $21.8 billion as cheaper generic copies took share.

    Eliquis 5 mg tablets · September 2026Image: U.S. National Library of Medicine
  • Eliquis (part of Legacy Portfolio)

    A blood thinner that prevents strokes and blood clots, sold together with partner Pfizer. It is the company's largest product, with $14.4 billion in 2025 sales, up 8%.

  • Opdivo (part of Growth Portfolio)

    A cancer medicine that helps the immune system attack tumors. It is used in many cancers, including lung, skin and colon cancer, and had about $10.0 billion in 2025 sales.

  • Revlimid and Pomalyst (part of Legacy Portfolio)

    Blood cancer medicines for multiple myeloma. Combined 2025 sales were about $5.7 billion, falling fast as generic versions arrive in the U.S.

    Revlimid 5 mg capsulesImage: U.S. National Library of Medicine
  • Orencia (part of Growth Portfolio)

    A medicine for rheumatoid arthritis and other immune conditions, with about $3.7 billion in 2025 sales.

    Orencia ClickJect 125 mg/mL autoinjector cartonImage: U.S. National Library of Medicine
We don't have each line's share of sales for this company yet.

Where its work physically happens, beyond headquarters:

  • Devens Manufacturing Campus — Devens, United States. This 700,000-square-foot campus supports process development and clinical and commercial manufacturing for biologics, including FDA-approved commercial CAR-T production.
  • Cruiserath Biologics Campus — Dublin, Ireland. The approximately $1 billion multi-product campus manufactures biologic drug substance, performs network-wide biologics release testing and materially expands BMS's global capacity for immuno-oncology medicines.
  • Summit West Campus — Summit, United States. The 90-acre, more-than-10-building campus operates around the clock to provide clinical and commercial autologous CAR-T supply.
  • Bothell Cell Therapy Facility — Bothell, United States. Operating since 2016, this facility produces engineered cell therapies and has supported BMS's investigational programs and commercial CAR-T launch.
  • Leiden CAR-T Production Centre — Leiden, Netherlands. Completed in 2025 as BMS's first European CAR-T manufacturing site, the facility is intended to expand regional supply and shorten delivery times for personalized cell therapies.
See them on the globe

Bristol Myers Squibb 2025 Annual Report (Form 10-K), Item 1 Business

How is the business doing?

Sales grew from $42.5B in 2020 to $48.2B in 2025, about 3% a year.

After paying for its upkeep and new investment, it had $9.3B of cash to spare in the 12 months to Sep 2026.

Sales$48.2B
20162025
Free cash flow$12.8B
20162025
Each bar is one fiscal year (2016–2025), summed from four published quarters; the latest is highlighted.

What does management say it's aiming for?

The company says it exists to discover, develop and deliver transformational medicines for patients facing serious diseases.

“discovering, developing and delivering transformational medicines for patients facing serious diseases”

Bristol Myers Squibb 2025 Annual Report (Form 10-K), Item 1 Business

Who is responsible for the plan?

Roles checked November 9, 2026.

What management says it is working on now:

Total revenue, Full year 2026 (raised July 2026 from $46.0–$47.5 billion)
About $49.0–$50.0 billion
Bristol Myers Squibb Q2 2026 results (8-K Exhibit 99.1)
Adjusted (non-GAAP) earnings per share, Full year 2026
$6.75–$7.00
Bristol Myers Squibb Q2 2026 results (8-K Exhibit 99.1)
Eliquis worldwide revenue growth, Full year 2026 vs. 2025
20%–25%
Bristol Myers Squibb Q2 2026 results (8-K Exhibit 99.1)
Gross margin, Full year 2026
About 69%–70%
Bristol Myers Squibb Q2 2026 results (8-K Exhibit 99.1)
Cost savings, By end of 2027
About $2.0 billion
Bristol Myers Squibb 2025 Annual Report (Form 10-K)
Goals in management's own numbers. A target is a promise, not a result.

What's changing right now?

Growth is picking up. In Q3 2026 it sold 7% more than a year earlier. The year before, quarters averaged 3%.

The share price is about where it was in Sep 2026, near $62.93.

Bull $154.97Base $80.20Bear $31.13Sep 21Nov 16 · $62.93
Daily closing prices we have recorded, set against our bear-to-bull range. Our price records start September 21, 2026.

Recently

Coming up

Our own estimate moved too: the base case went from $64.93 to $80.20 a share between our last two valuations. The biggest reason: Eliquis worldwide quarterly revenue moved from an unreported prior value to $4.7B, as reported in BMS Q3 2026 results, Eliquis worldwide quarterly sales in USD.

What could go wrong?

No business is a sure thing. These are the risks we found, starting with the ones the company itself names. Where a risk would change part of the valuation, it says which.

  1. Big drugs losing patent protection

    Cheaper generic copies are expected to cut sales of key drugs once their patents expire. The company expects U.S. exclusivity for Eliquis and Opdivo to end around 2028. Revlimid and Pomalyst sales are already falling sharply because of generics.

    From the company's own filingsWould hit how fast sales growBristol Myers Squibb 2025 Annual Report (Form 10-K), Items 1 and 1A

  2. Government-set drug prices

    Under the Inflation Reduction Act, Medicare now sets prices for some drugs. These prices apply to Eliquis from 2026 and to Pomalyst from 2027, and Orencia was selected for 2028. More of the company's products could be chosen later.

    From the company's own filingsWould hit how fast sales growBristol Myers Squibb 2025 Annual Report (Form 10-K), Item 1A Risk Factors

  3. Pressure to match lower foreign prices

    The U.S. administration is pushing drugmakers to charge Americans no more than other wealthy countries pay. In December 2025 the company agreed to discounts and free Eliquis for Medicaid in exchange for tariff relief, but those protections could end.

    From the company's own filingsWould hit how much of each sale it keepsBristol Myers Squibb 2025 Annual Report (Form 10-K), Item 1A Risk Factors

  4. New drugs may fail or launch slowly

    Future growth depends on newer products and drugs still in testing. Clinical trials can fail, regulators can delay approvals, and launches can sell less than hoped.

    From the company's own filingsWould hit how fast sales growBristol Myers Squibb 2025 Annual Report (Form 10-K), Item 1A Risk Factors

  5. Higher debt from acquisitions

    Buying companies such as Mirati, Karuna and RayzeBio added a lot of debt, and S&P lowered the company's credit rating from A+ to A. Long-term debt was about $42 billion at mid-2026.

    From the company's own filingsBristol Myers Squibb Q2 2026 Quarterly Report (Form 10-Q)

  6. Unresolved tax dispute

    The company is still appealing an IRS review of how it priced transactions between its own units in 2008–2012. The timing is uncertain, and the outcome could be material.

    From the company's own filingsWould hit the tax it paysBristol Myers Squibb Q2 2026 Quarterly Report (Form 10-Q)

  7. Opdivo's estimated minimum U.S. exclusivity ends in 2028.

    From our researchWould hit how fast sales growBMS 2025 Form 10-K

  8. Q2 selling and administrative expense rose with new-product launches.

    From our researchWould hit how much of each sale it keepsBMS Q2 2026 results

Is it a good business?

From 2016 to 2025 it earned between -55% and 38% on its shareholders' equity, a median of 20%.

derived computed from the filingsassumption cost of capital from the latest valuation
Return on equity38%
20162025
Return on invested capital is operating profit after tax (at the median effective rate, 18%) over debt plus equity less cash at each fiscal year end. Return on equity is net income over equity. Both are computed from published quarters.

The number of shares has held roughly steady over the past year.

It owes $33.3B more than it holds in cash. An operating-profit comparison is unavailable from the published quarters.

What might it be worth?

The Valuation snapshot at the top of this page shows the answer. This is how we got there. A share is a slice of the business, so what a share is worth depends on what the business can earn for its owners from here on. We estimate that three ways, from cautious to hopeful, and call the result .

Today a share costs $62.93. Our put its value between $31.13 and $154.97, with $80.20 in the middle. Underneath sit two simpler checks: what it would cost to rebuild the business, its , and what today's profit is worth with no growth at all, its .

Bear case, $31.13

The recent sales recovery fades as cheaper competitors take business from major medicines and newer treatments struggle to fill the gap.

Base case, $80.20

The recent sales recovery helps newer medicines cushion losses from older drugs, allowing the business to recover after a difficult stretch.

Bull case, $154.97

The recent sales acceleration continues as newer medicines replace older products and successful launches help the company earn more from each sale.

Another way in: instead of asking what the business is worth, ask what today's price assumes it will do.

Why the gap?

The price expects less than we do.Margin of safety: 22%

At today's $62.93, the price makes sense if sales shrink about 4.6% a year. We assume they shrink 0.3%. Over the last 5 years, sales grew 1.9% a year.

−6%−4%−2%0%+2%+4%Price needs −4.6%We assume −0.3%Past 5 yrs 1.9%

Or, if sales shrink 0.3% as we assume, the price works with a profit margin of 27.1% (we assume 33.0%).

Keep in mind: a low price can mean investors see a risk that isn't in the filings yet. Check the Full research tab for what could go wrong.

Do you think sales will shrink about 4.6% a year?

Try your own numbers

We're not very sure of this range: it scores 45 out of 100 on our checks. The weakest point is terminal-value dependency.

Test the assumptions

Our base value of $80.20 rests on three assumptions. Change any of them to see how the value per share responds.

  • Revenue growth, 5-year average-0.3%
  • Operating margin33.0%
  • Long-term growth rate1.5%

This is an educational explanation built from public filings and our own research, not investment advice. It does not tell you whether to buy or sell anything.

Base estimate

$80.20 27.4%

Build